Home › Research › Drug development
Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005-2024)
Zhang Y, Lv Y, Yang T, Liu Q, Guo Q.. Journal of Alzheimer's disease reports, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Background Alzheimer's disease (AD) and insulin resistance (IR) share intersecting pathological pathways, with IR increasingly implicated in AD pathogenesis. Systematic bibliometric analyses mapping the evolution of this interdisciplinary field remain limited. Objective To quantify global research trends, collaboration networks, knowledge structures, and emerging frontiers in IR-AD research from 2005-2024. Methods We analyzed 2676 publications from the Web of Science Core Collection. Using VOSviewer, CiteSpace, and bibliometrix R package, we conducted quantitative analyses and visualized multiple dimensions including annual publications/citations, countries/regions, institutions, journals, authors, references, and keywords. Results Annual publications grew steadily, peaking at 267 in 2022. The United States dominated productivity (942 papers, 35.2%) and citations (88,170). The University of Kentucky was the top institution (53 papers), while the Journal of Alzheimer's Disease led in output (214 papers) and co-citations (8046). Keyword analysis revealed three clusters: metabolic dysregulation, molecular pathology, and neuroimmune responses. Emerging frontiers highlight neuroimmune mechanisms, with current hotspots focusing on NLRP3 inflammasome activation, gut-brain axis dysregulation, glucose transporter impairment, and therapeutic repurposing of GLP-1 agonists. Conclusions These findings underscore IR-AD as a critical intersection of metabolic and neurodegenerative pathways, advocating for targeted therapies addressing neuroinflammation and cerebral metabolism. By delineating global trends, this study provides a roadmap for future research to bridge translational gaps in AD pathogenesis and treatment.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, Y., Lv, Y., Yang, T., Liu, Q., & Guo, Q. (2025). Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005-2024). Journal of Alzheimer's disease reports. https://doi.org/10.1177/25424823251361056
Vancouver
Zhang Y, Lv Y, Yang T, Liu Q, Guo Q. Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005-2024). Journal of Alzheimer's disease reports. 2025. doi:10.1177/25424823251361056. PMID: 40687177.
BibTeX
@article{zhang2025-40687177,
author = {Zhang, Y. and Lv, Y. and Yang, T. and Liu, Q. and Guo, Q.},
title = {{Insulin resistance and Alzheimer's disease: Exploring research hotspots and frontiers from a bibliometric and visual analysis (2005-2024)}},
journal = {Journal of Alzheimer's disease reports},
year = {2025},
doi = {10.1177/25424823251361056},
pmid = {40687177},
url = {https://doi.org/10.1177/25424823251361056}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Annual publications grew steadily, peaking at 267 in 2022.
- Keyword analysis revealed three clusters: metabolic dysregulation, molecular pathology, and neuroimmune responses.
- Conclusions These findings underscore IR-AD as a critical intersection of metabolic and neurodegenerative pathways, advocating for targeted therapies addressing neuroinflammation and cerebral metabolism.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants2,676
- Effect size35.2%
- Evidence strengthLow
How this study scored 59/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 34 of the 58 points we could judge it on, which is 59 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease reports) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,676 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40687177) |
| Free to read | 2 / 2 | Free to read |
| Points | 34 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 34 of the 58 points we could judge it on is 59 out of 100. |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development
Also tagged “bibliometric”
2 studies in the library carry the topic tag “bibliometric”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.